Translational immunotoxicology of immunomodulatory monoclonal antibodies

Drug Discovery Today: Technologies

Volumn 21-22, Issue , 2016, Pages 85-93

  Brennan, Frank R ^a   Kiessling, Andrea ^a  

^a UCB PHARMA   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; IMMUNOLOGIC FACTOR;

CANCER RISK; HUMAN; IMMUNOPHARMACOLOGY; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTOXICITY; IN VITRO STUDY; IN VIVO STUDY; INFECTION RISK; NONHUMAN; PRACTICE GUIDELINE; PREDICTIVE VALUE; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SPECIES DIFFERENCE; TOXICITY TESTING; ANIMAL; PRECLINICAL STUDY; TRANSLATIONAL RESEARCH;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG EVALUATION, PRECLINICAL; HUMANS; IMMUNOLOGIC FACTORS; TOXICITY TESTS; TRANSLATIONAL MEDICAL RESEARCH;

EID: 85003881388     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2016.08.002     Document Type: Review

References (44)

1. [1] Kotsovilis, S., Andreakos, E., Therapeutic human monoclonal antibodies in inflammatory diseases. Methods Mol Biol 106 (2014), 37–59.
2. [2] Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–456.
3. [3] Murdaca, G., Spanò, F., Contatore, M., Guastalla, A., Penza, E., Magnani, O., et al. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?. Expert Opin Drug Saf 15 (2016), 43–52.
4. [4] Major, E.O., Nath, A., A link between long-term natalizumab dosing in MS and PML: putting the puzzle together. Neurol Neuroimmunol Neuroinflamm, 3(3), 2016, e235, 10.1212/NXI.0000000000000235.
5. [5] Maude, S.L., Barrett, D., Teachey, D.T., Grupp, S.A., Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J 20 (2014), 119–122.
6. [6] Ryan, J.M., Wasser, J.S., Adler, A.J., Vella, A.T., Enhancing the safety of antibody-based immunomodulatory cancer therapy without compromising therapeutic benefit: can we have our cake and eat it too?. Expert Opin Biol Ther 16 (2016), 655–674.
7. [7] Maggi, E., Vultaggio, A., Matucci, A., Acute infusion reactions induced by monoclonal antibody therapy. Expert Rev Clin Immunol 7 (2011), 55–63.
8. [8] Chung, C.H., Mirakhur, B., Chan, E., Le, Q.T., Berlin, J., Morse, M., et al. Cetuximab-induced anaphylaxis and IgE specific for galactose α-1,3-galactose. N Engl J Med 358 (2008), 1109–1117.
9. [9] Vultaggio, A., Nencini, F., Pratesi, S., Petroni, G., Maggi, E., Matucci, A., Manifestations of antidrug antibodies response: hypersensitivity and infusion reactions. J Interferon Cytokine Res 34 (2014), 946–952.
10. [10] Brennan, F.R., Cauvin, A., Tibbitts, J., Wolfreys, A., Optimized nonclinical safety assessment strategies supporting clinical development of therapeutic monoclonal antibodies targeting inflammatory diseases. Drug Dev Res 75 (2014), 115–161.
11. [11] ICHS6 (R1), Preclinical safety evaluation of biotechnology-derived pharmaceuticals. Step 2. Addendum. 2009 Available at: http://www.ich.org/LOB/media/MEDIA5784.pdf.
12. [12] ICHS8, Immunotoxicity studies for human pharmaceuticals, 2005 Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Safety/S8/Step4/S8_Guideline.pdf.
13. [13] Walker, M., Makropoulos, D., Achuthanandam, R., Bugelski, P.J., Recent advances in the understanding of drug-mediated infusion reactions and cytokine release syndrome. Curr Opin Drug Discov Dev 13 (2010), 124–135.
14. [14] Finco, D., Grimaldi, C., Fort, M., Walker, M., Kiessling, A., Wolf, B., et al. Cytokine release assays: current practices and future directions. Cytokine 66 (2014), 143–155.
15. [15] Wolf, B., Morgan, H., Krieg, J., Gani, Z., Milicov, A., Warncke, M., et al. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans. Cytokine 60 (2012), 828–837.
16. [16] Stebbings, R., Findlay, L., Edwards, C., Eastwood, D., Bird, C., North, D., et al. ‘Cytokine storm’ in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 179 (2006), 3325–3331.
17. [17] Bussiere, J.L., Martin, P., Horner, M., Couch, J., Flaherty, M., Andrews, L., et al. Alternative strategies for toxicity testing of species-specific biopharmaceuticals. Int J Toxicol 28 (2009), 230–253.
18. [18] Nguyen, D.H., Hurtado-Ziola, N., Gagneux, P., Varki, A., Loss of Siglec expression on T lymphocytes during human evolution. Proc Natl Acad Sci USA 103 (2006), 7765–7770.
19. [19] Suntharalingam, G., Perry, M.R., Ward, S., Brett, S.J., Castello-Cortes, A., Brunner, M.D., et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355 (2006), 1018–1028.
20. [20] Eastwood, D., Findlay, L., Poole, S., Bird, C., Wadhwa, M., Moore, M., et al. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells. Br J Pharmacol 161 (2010), 512–526.
21. [21] Gogishvili, T., Langenhorst, D., Lühder, F., Elias, F., Elflein, K., Dennehy, K.M., et al. Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice. PLoS ONE, 4(2), 2009, e4643, 10.1371/journal.pone.0004643.
22. [22] Frigault, M.J., June, C.H., Predicting cytokine storms: it's about density. Blood, 118, 2011, 672.
23. [23] Hussain, K., Hargreaves, C.E., Roghanian, A., Oldham, R.J., Chan, H.T., Mockridge, C.I., et al. Upregulation of FcγRIIb on monocytes is necessary to promote the superagonist activity of TGN1412. Blood 125 (2015), 102–110.
24. [24] Rogers, K.A., Scinicariello, F., Attanasio, R., IgG Fc receptor III homologues in nonhuman primate species: genetic characterization and ligand interactions. J Immunol 177 (2006), 3848–3856.
25. [25] Warncke, M., Calzascia, T., Coulot, M., Balke, N., Touil, R., Kolbinger, F., et al. Different adaptations of IgG effector function in human and nonhuman primates and implications for therapeutic antibody treatment. J Immunol 188 (2012), 4405–4411.
26. [26] Flaherty, M.M., MacLachlan, T.K., Troutt, M., Magee, T., Tuaillon, N., Johnson, S., et al. Nonclinical evaluation of GMA161 – an antihuman CD16 (FcγRIII) monoclonal antibody for treatment of autoimmune disorders in CD16 transgenic mice. Toxicol Sci 125 (2012), 299–309.
27. [27] Nimmerjahn, F., Ravetsch, J.V., Fcγ receptors as regulators of immune responses. Nat Rev Immunol 8 (2008), 34–47.
28. [28] Haley, P.J., Species differences in the structure and the function of the immune system. Toxicology 188 (2003), 49–71.
29. [29] Muller, P.Y., Brennan, F.R., Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies. Clin Pharmacol Ther 85 (2009), 247–258.
30. [30] Price, K.D., Rao, G.K., Biological therapies for cancer. Nonclinical development of novel biologics, biosimilars, vaccines and specialty biologics, 2013, 10.1016/B978-0-12-394810-6.00013-7.
31. [31] Sasseville, V., Mansfield, K., Overview of known non-human primate pathogens with potential to effect colonies used for toxicity testing. J Immunotoxicol 7 (2009), 79–92.
32. [32] Price, K.D., Bacterial infections in cynomolgus monkeys given small molecule immunomodulatory antagonists. J Immunotoxicol 7 (2010), 128–137.
33. [33] Burleson, G.R., Burleson, F.G., Testing human biologicals in animal host resistance models. J Immunotoxicol 5 (2008), 23–31.
34. [34] Luster, M.I., Portier, C., Pait, D.G., Rosenthal, G.J., Germolec, D.R., Corsini, E., et al. Risk assessment in immunotoxicology. II. Relationships between immune and host resistance tests. Fundam Appl Toxicol, 1993, 71–82.
35. [35] Haggerty, H.G., Price, K., Shenton, J.M., Immunotoxicity of biopharmaceutics. Ref Mod Biomed Res, 2014, 10.1016/B978-0-12-801238-3, 02008-0.
36. [36] Mittal, D., Gubin, M.M., Schreiber, R.D., Smyth, M.J., New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol 27 (2014), 16–25.
37. [37] Ponce, R.A., Gelzleichter, T., Haggerty, H.G., Heidel, S., Holdren, M.S., Lebrec, H., et al. Immunomodulation and lymphoma in humans. J Immunotoxicol 11 (2014), 1–12.
38. [38] Vahle, J.L., Finch, G.L., Heidel, S.M., Hovland, D.N., Jr, Ivens, I., Parker, S., et al. Carcinogenicity assessment of biotechnology-derived pharmaceuticals: a review of approved molecules and best practice recommendations. Toxicol Pathol 38 (2010), 522–553.
39. [39] Bugelski, P.J., Volk, A., Walker, M.R., Krayer, J.H., Martin, P., Descotes, J., Critical review of preclinical approaches to evaluate the potential of immunosuppressive drugs to influence human neoplasia. Int J Toxicol 29 (2010), 435–466.
40. [40] Lebrec, H., Brennan, F.R., Haggerty, H., Herzyk, D., Kamperschroer, C., Maier, C.C., et al. HESI/FDA workshop on immunomodulators and cancer risk assessment: building blocks for a weight-of-evidence approach. Regul Toxicol Pharmacol 75 (2016), 72–80.
41. [41] Yang, Z., Wang, H, Salcedo, T.W., Suchard, S.J., Xie, J.H., Schneeweis, L.A., et al. Integrated pharmacokinetic/pharmacodynamic analysis for determining the minimal anticipated biological effect level of a novel anti-CD28 receptor antagonist BMS-931699. J Pharmacol Exp Ther 355 (2015), 506–515.
42. [42] Bugelski, P.J., Martin, P.L., Concordance of preclinical and clinical pharmacology and toxicology of therapeutic monoclonal antibodies and fusion proteins: cell surface targets. Br J Pharmacol 166 (2012), 823–846.
43. [43] Martin, P.L., Bugelski, P.J., Concordance of preclinical and clinical pharmacology and toxicology of monoclonal antibodies and fusion proteins: soluble targets. Br J Pharmacol 166 (2012), 806–822.
44. [44] Polson, A.G., Fuji, R.N., The successes and limitations of preclinical studies in predicting the pharmacodynamics and safety of cell-surface-targeted biological agents in patients. Br J Pharmacol 166 (2012), 1600–1602.